Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

BenzingaOct 3 07:42 ET

Palvella Therapeutics Awarded Up to $2.6 Million Grant From the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

GlobeNewswireOct 3 07:30 ET

Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 Loss per Share (Vs US$3.63 Profit in 2Q 2023)

Yahoo FinanceAug 19 06:07 ET

We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Yahoo FinanceAug 17 09:10 ET

Pieris Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

SECAug 14 16:53 ET · Announcements

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.

PR NewswireJul 24 17:03 ET